You are here: Industry Insights > Pharma in China > Chinese-produced New Drugs Approved for Marketing in 2018

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate

Neohesperidin

Advantame

Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench

Pharma and Food Grade, USP/FCC Neotame Sweetener E961

Trilobatin

Chinese-produced New Drugs Approved for Marketing in 2018

PharmaSources/caicaiJanuary 21, 2019

Tag: new drugs , Approved , 2018 , Chinese-produced Drugs

Favorites

Chinese-produced New Drugs Approved for Marketing in 2018:

Chinese-produced New Drugs Approved for Marketing in 2018

(Source: NMPA website, company announcements)

Pharmaceutical product name	Trade name	Registration classification	Company	Approval date	Indication
Recombinant Cytokine Gene Derived Protein Injection	Novaferon	Biological product for treatment 1	Genova Inc.	Apr. 20, 2018	HBV
Anlotinib Hydrochloride Capsules	FOCUS V	Chemical drug 1	Chiatai Tianqing	May 17, 2018	Locally advanced or metastatic NSCLC
Mecapegfilgrastim Injection	Aiduo	Biological product for treatment 9	Hengrui Medicine	May 17, 2018	Neutropenia
Albuvirtide for Injection	Aikening	Chemical drug 1	Frontier Biotechnologies	May 30, 2018	HIV-1
Danoprevir Sodium Tablets	Ganovo	Chemical drug 1	Ascletis	June 15, 2018	HCV
Pegylated Recombinant Interferon Variant Injection	Kailiwei	Biological product for treatment 9	Beijing Kawin	July 6, 2018	HCV
Pyrotinib Maleate Tablets	Airuini	Chemical drug 1	Hengrui Medicine	Aug. 17, 2018	Human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer
Fruquintinib Capsules	Elunate	Chemical drug 1	Hutchison MediPharma	Sep. 13, 2018	Colorectal cancer
Toripalimab Injection	Tuoyi	Biological product for treatment 1	Junshi Biosciences	Dec. 21, 2018	Melanoma
Sintilimab Injection	Tyvyt	Biological product for treatment 1	Innovent	Dec. 27, 2018	Classical Hodgkin's lymphoma
Jinrong Xiaopi Granules	/	TCM 6.1	Kangyuan Pharmaceutical	Dec. 27, 2018	Cyclomastopathy: intermingled phlegm and blood stasis and disharmony of the thoroughfare and conception vessels

About the Author:

Caicai, a Master of Pharmacy from Shanghai Jiaotong University, used to work in the Institute of Science and Technical Information. Currently as a practitioner in the drug surveillance system, she is good at interpreting industry regulations, pharmaceutical research developments, etc.

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:Chinese-produced new drugs to be marketed soon in 2019

Next:A Review of the Chinese-produced New Drugs Marketed in 2018

China's Innovative Drugs Hunt for Billion Dollar Molecule

XiaobinDecember 20, 2024

The Central Economic Work Conference in 2023 emphasized the need to promote industrial innovation through, especially by fostering new industries, new models, and new growth engines and developing new forms of productive forces.

Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global

YiDecember 20, 2024

New Pathways for Innovation and Transformation of Local Pharmaceutical Companies

XiaobinDecember 20, 2024

Chinese-produced New Drugs Approved for Marketing in 2018 | Pharmasources.com

Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field

xiaobinDecember 20, 2024

Recently, Northeast Pharm announced its plan to acquire a 70% stock equity in Dingcheng Taiyuan for a total cash consideration of approximately RMB 187 million, thereby obtaining controlling stake in the company.

Chinese-produced New Drugs Approved for Marketing in 2018

About the Author:

Related News

China's Innovative Drugs Hunt for Billion Dollar Molecule

Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global

New Pathways for Innovation and Transformation of Local Pharmaceutical Companies

Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field

You may like
More>>

Chinese-produced New Drugs Approved for Marketing in 2018

About the Author:

Related News

China's Innovative Drugs Hunt for Billion Dollar Molecule

Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global

New Pathways for Innovation and Transformation of Local Pharmaceutical Companies

Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field

You may likeMore>>

You may like
More>>